Publications (149,068)

Search

Rediscovering majority logic in the post-CMOS era: A perspective from in-memory computing

Reuben JR (2020)

Journal article

(Un-)Doing Theory. Theater, Theorie, Schule in theaterwissenschaftlicher Perspektive

Bormann HF (2020)

Journal article, Original article

Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. (2020)

Conference contribution

Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC)

Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. (2020)

Conference contribution

EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation

Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. (2020)

Conference contribution

GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status

Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. (2020)

Conference contribution

Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. (2020)

Conference contribution

Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases

Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al. (2020)

Conference contribution

Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results

Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. (2020)

Conference contribution

Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC

Vogel A, Mueller DW, De Toni E, Siegler GM, Lindig U, Mueller T, Schultheiss M, et al. (2020)

Conference contribution

‹ 1 ... 4,032 4,033 4,034 4,035 4,036 ... 14,907 ›